Status:
COMPLETED
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
Lead Sponsor:
Alumis Inc
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Healthy Men and woman age 18-60
- Able to provide written informed consent
- Females can not be pregnant or lactating
Exclusion
- Prior exposure to ESK-001
- History of malignancy within the last 10 years
- Positive for HIV, Hepatitis B or C
- History of tuberculosis
- Positive test for alcohol or drugs
Key Trial Info
Start Date :
March 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2022
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05330858
Start Date
March 17 2022
End Date
September 20 2022
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alumis Central Site
Glendale, California, United States, 91206